San Diego drug delivery company Sonrgy snagged exclusive rights to an ultrasound-based nanotech delivery platform conceived at the University of California, San Diego.
For an undisclosed amount, Pfizer signed a deal to use the San Diego company's TriGrid intramuscular electroporation system, which creates temporary pores in cell membranes, allowing vaccines to become more thoroughly entrenched. Pfizer is interested in making the technology a part of its preclinical cancer vaccine-based immunotherapy research program, according to a release from Ichor.
Zosano Pharma, the developer of a microneedle patch for various applications, has signed on with pharma giant Novo Nordisk to deliver semaglutide, an analogue used to treat Type 2 diabetes. Zosano is set to collect $60 million for the first product in the deal and $55 million for each additional one.
California microRNA specialist Regulus Therapeutics renewed an almost-four-year-old partnership with Sanofi to help develop its RNA programs further for orphan and oncology purposes, collecting a $10 million equity investment in the process.
MIT professor and entrepreneur Robert Langer is behind another innovative nanotechnology application for drug delivery, this time helping develop a model that could help researchers understand the way nanoparticles penetrate blood vessel walls.
Israel's Oramed touted results from a successful Phase IIa trial of its insulin pill, saying the oral Type 2 diabetes treatment is safe and well-tolerated. But since then, some analysts and media outlets have criticized the company for being less than forthcoming about the data.
Canadian delivery specialist IntelGenx Technologies and Israeli partner RedHill Biopharma say they can turn the FDA's rejection of their dissolvable migraine film around quickly because the regulators didn't take issue with the study data--rather, third-party manufacturing practices were to blame.
A new delivery system from Texas A&M University uses a hydrogel material to hold drugs and deliver drugs through microscopic holes in its structure.
A University of Rhode Island researcher won a National Institutes of Health grant of $1.3 million to further study the use of cancer-targeting copper sulfide nanoparticles for breast cancer.
To make drug delivery structures of a particular size and shape, researchers have developed gold nanoparticle building blocks that can be "glued" together with bits of DNA. This could have particular importance in delivering drugs to treat breast cancer.
Nanodiamonds have been used in drug delivery for several years, most notably to deliver chemotherapy with fewer side effects. Now researchers have added a component to the tiny vehicles that could improve their delivery properties: They've covered them in silk.
Artificial pancreas news: U.K. researchers unveil device, Animas snags Canadian approval of closed-loop system
Two more advances in insulin pump technology this week offer glimpses of what could soon be an actual artificial pancreas, the combination insulin pump and glucose monitor long desired in the diabetes market.
Evoke Pharma showed in a recent study that its nasal spray for the delivery of a generic gastrointestinal drug performed better than the traditional oral form. The nasal delivery method could help patients take the drug when they are suffering from nausea and have difficulty swallowing a pill.
German devicemaker Biotronik launched its Passeo-18 Lux drug-releasing balloon in Europe, backed by stellar results.
Researchers at Vanderbilt University have developed a biodegradable network of nanoparticles that can deliver small bits of genetic material and promote blood vessel growth and tissue regeneration.
Connecticut-based NanoViricides, with its novel antiviral nanotech delivery, pulled in $20 million in an offering from a combination of unnamed institutional investors and existing shareholders.
Researchers have found that gravity and electrostatics are two important factors at play between cell membranes and drug reservoirs. With these new findings, the scientists hope to create systems that deliver cancer drugs slowly and continuously.
High-density lipoproteins are a key component in the transportation of molecules such as cholesterol and fats inside the body. And by using a synthetic nanoparticle version of these natural vehicles, researchers have found a way to deliver drugs to the heart that could potentially prevent repeat heart attacks or stroke.
Novartis launched a topical gel in India designed to treat pain associated with osteoarthritis, rheumatism and injury.